Abstract
A key challenge in pulmonary gene therapy for cystic fibrosis is to provide long-term correction of the genetic defect. This may be achievable by targeting airway epithelial stem/progenitor cells with an integrating vector. Here, we evaluated the ability of a lentiviral vector, derived from the simian immunodeficiency virus and pseudotyped with F and HN envelope proteins from Sendai virus, to transduce progenitor basal cells of the mouse nasal airways. We first transduced basal cell-enriched cultures ex vivo and confirmed efficient transduction of cytokeratin-5 positive cells. We next asked whether progenitor cells could be transduced in vivo. We evaluated the transduction efficiency in mice pretreated by intranasal administration of polidocanol to expose the progenitor cell layer. Compared to control mice, polidocanol treated mice demonstrated a significant increase in the number of transduced basal cells at 3 and 14 days post vector administration. At 14 days, the epithelium of treated mice contained clusters (4 to 8 adjacent cells) of well differentiated ciliated, as well as basal cells suggesting a clonal expansion. These results indicate that our lentiviral vector can transduce progenitor basal cells in vivo, although transduction required denudation of the surface epithelium prior to vector administration.
Keywords: Cystic fibrosis, Gene therapy, Lentivirus, Progenitor basal cells, Polidocanol.
Current Gene Therapy
Title:Ex Vivo and In Vivo Lentivirus-Mediated Transduction of Airway Epithelial Progenitor Cells
Volume: 15 Issue: 6
Author(s): Giulia Leoni, Marguerite Y. Wasowicz, Mario Chan, Cuixiang Meng, Raymond Farley, Steven L. Brody, Makoto Inoue, Mamoru Hasegawa, Eric W.F.W. Alton and Uta Griesenbach
Affiliation:
Keywords: Cystic fibrosis, Gene therapy, Lentivirus, Progenitor basal cells, Polidocanol.
Abstract: A key challenge in pulmonary gene therapy for cystic fibrosis is to provide long-term correction of the genetic defect. This may be achievable by targeting airway epithelial stem/progenitor cells with an integrating vector. Here, we evaluated the ability of a lentiviral vector, derived from the simian immunodeficiency virus and pseudotyped with F and HN envelope proteins from Sendai virus, to transduce progenitor basal cells of the mouse nasal airways. We first transduced basal cell-enriched cultures ex vivo and confirmed efficient transduction of cytokeratin-5 positive cells. We next asked whether progenitor cells could be transduced in vivo. We evaluated the transduction efficiency in mice pretreated by intranasal administration of polidocanol to expose the progenitor cell layer. Compared to control mice, polidocanol treated mice demonstrated a significant increase in the number of transduced basal cells at 3 and 14 days post vector administration. At 14 days, the epithelium of treated mice contained clusters (4 to 8 adjacent cells) of well differentiated ciliated, as well as basal cells suggesting a clonal expansion. These results indicate that our lentiviral vector can transduce progenitor basal cells in vivo, although transduction required denudation of the surface epithelium prior to vector administration.
Export Options
About this article
Cite this article as:
Leoni Giulia, Y. Wasowicz Marguerite, Chan Mario, Meng Cuixiang, Farley Raymond, L. Brody Steven, Inoue Makoto, Hasegawa Mamoru, W.F.W. Alton Eric and Griesenbach Uta, Ex Vivo and In Vivo Lentivirus-Mediated Transduction of Airway Epithelial Progenitor Cells, Current Gene Therapy 2015; 15 (6) . https://dx.doi.org/10.2174/1566523215666151016123625
DOI https://dx.doi.org/10.2174/1566523215666151016123625 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
In Vivo Delivery of Morpholino Oligos by Cell-Penetrating Peptides
Current Pharmaceutical Design Interleukin-6 and Lung Inflammation: Evidence for a Causative Role in Inducing Respiratory System Resistance Increments
Inflammation & Allergy - Drug Targets (Discontinued) Vascular and Cellular Calcium in Normal and Hypertensive Pregnancy
Current Clinical Pharmacology Gene Therapy for Lysosomal Storage Diseases: Progress, Challenges and Future Prospects
Current Pharmaceutical Design Role of the Autonomic Nervous System and Neuropeptides in the Development of Obesity in Humans: Targets for Therapy?
Current Pharmaceutical Design Adverse Bioeffects of Ultrasound Contrast Agents Used in Echocardiography: True Safety Issue or “Much Ado About Nothing”?
Current Vascular Pharmacology A Mini-Review on Cardiovascular and Hematological Complications of COVID-19
Coronaviruses SARS-Coronavirus 2, A Metabolic Reprogrammer: A Review in the Context of the Possible Therapeutic Strategies
Current Drug Targets Ivermectin in Human Medicine, An Overview of the Current Status of Its Clinical Applications
Current Pharmaceutical Biotechnology Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Hybrid Bioactive Heterocycles as Potential Antimicrobial Agents: A Review
Mini-Reviews in Medicinal Chemistry T Cell Costimulatory and Inhibitory Receptors as Therapeutic Targets for Inducing Anti-Tumor Immunity
Current Cancer Drug Targets Microscopies at the Nanoscale for Nano-Scale Drug Delivery Systems
Current Drug Targets Torsades de Pointes in Patients with Polymyalgia Rheumatica
Current Pharmaceutical Design Actions of Relaxin on Non-Reproductive Tissues
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Assessment of Mobility Status and Risk of Mobility Disability in Older Persons
Current Pharmaceutical Design Heart Failure Pharmacotherapy: Differences Between Adult and Paediatric Patients
Current Medicinal Chemistry Integrins Modulate Cellular Fibrogenesis at Multiple Levels: Regulation of TGF-β Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Natural Products as Anti-glycation Agents: Possible Therapeutic Potential for Diabetic Complications
Current Diabetes Reviews The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters